Curcumin and nano-curcumin applications in psychiatric disorders

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Psychiatric disorders lead to significant long-term disability.
• Existing treatments are not always effective or can lead to treatment resistance.
• Inflammation is increasingly recognized as a key factor in psychiatric disorder pathogenesis.

Purpose of the Study:

• To review the therapeutic potential of curcumin and its nanoformulations for psychiatric disorders.
• To examine evidence for curcumin in major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders.
• To identify research gaps and future directions for curcumin in psychiatric treatment.

Main Methods:

• Comprehensive literature review of studies on curcumin and psychiatric disorders.
• Analysis of clinical trials and preclinical research.
• Evaluation of curcumin's anti-inflammatory and neuroprotective mechanisms.

Main Results:

• Curcumin shows promise as an antidepressant, particularly for major depressive disorder (MDD), as monotherapy or adjunct treatment.
• Evidence for curcumin's efficacy in bipolar disorder and schizophrenia is limited and requires more robust clinical trials.
• Nanoformulations of curcumin, such as liposomes and nanoparticles, offer potential for improved delivery and efficacy.

Conclusions:

• Curcumin exhibits potential therapeutic benefits for certain psychiatric conditions, notably depression.
• Further high-quality clinical trials are essential to establish optimal dosages, formulations, and treatment durations for various psychiatric disorders.
• Nanoformulations and advanced delivery systems warrant further investigation to enhance curcumin's therapeutic application in psychiatry.